BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, has filed for an initial public offering. The company said Tuesday in a filing with ...

BioAge Labs has appointed former GSK CEO Jean-Pierre Garnier as chair of its board of directors, bringing the pharma veteran back into the anti-aging space 16 years after he made a big bet on the ...

RICHMOND, Calif.--(BUSINESS WIRE)--BioAge Labs, Inc. (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the ...

(Reuters) -BioAge Labs, an obesity therapy-focused startup that has also collaborated with Eli Lilly, filed for an initial public offering in the United States on Tuesday as it looks to capitalize ...

Sept 3 (Reuters) - BioAge Labs, an obesity therapy-focused startup that has also collaborated with Eli Lilly (LLY.N), opens new tab, filed for an initial public offering in the United States on ...

BioAge Labs filed confidentially on May 31, 2024. Goldman Sachs, Morgan Stanley, Jefferies, and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.

(Reuters) - BioAge Labs, a biotech startup collaborating with Eli Lilly for its obesity therapy, said on Tuesday it had filed for an initial public offering in the United States. The move comes months ...

The move comes months after BioAge raised $170 million in a funding round led by life sciences investment firm Sofinnova Investments. BioAge said it will list its shares on the Nasdaq under the ...

Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...

Less than a week after Richmond-based BioAge Labs Inc. filed paperwork for an initial public offering, Foster City's Terns Pharmaceuticals Inc. said looks to translate positive clinical trial data ...